Facts of KYPROLIS( Carfilzomib ) for Injection ?
- Medicine Name: Kyprolis
- Date of Approval: 20.07.2012
- Company Name: Onyx Pharmaceuticals
Kyprolis® (carfilzomib) for Injection, a proteasome inhibitor, is approved for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.
The U.S. Food and Drug Administration (FDA) approved it on 20 July 2012
ADCETRIS should not be taken alone.
It is not known if ADCETRIS is safe and effective in children under 18 years of age.
Supplied: KYPROLIS (carfilzomib) for Injection is supplied as an individually cartoned single-use vial containing a dose of 60 mg of carfilzomib as a white to off-white lyophilized cake or powder. NDC 76075-101-01, 60 mg carfilzomib per vial
Storage and Handling: Unopened vials should be stored refrigerated (2°C to 8°C; 36°F to 46°F). Retain in original package to protect from light.